Paul Sax, MD
May 23rd, 2012
Panel: Azithromycin and Cardiovascular Risk
Paul Sax, MD, Joseph S. Ross, MD, MHS and Jeffrey Lance Anderson, MD
Three experts offer perspective on a large database study showing an association between azitrhromycin use and increased risk for cardiovascular death.
NEJM Journal Watch — Recent Cardiology Articles- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension